Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-tn8tq Total loading time: 0 Render date: 2024-06-29T16:27:25.700Z Has data issue: false hasContentIssue false

25 - STAT signaling as a molecular target for cancer therapy

from Part 2.1 - Molecular pathways underlying carcinogenesis: signal transduction

Published online by Cambridge University Press:  05 February 2015

Hua Yu
Affiliation:
Beckham Research Institute, City of Hope, Duarte, CA, USA
Richard Jove
Affiliation:
Beckham Research Institute, City of Hope, Duarte, CA, USA
Edward P. Gelmann
Affiliation:
Columbia University, New York
Charles L. Sawyers
Affiliation:
Memorial Sloan-Kettering Cancer Center, New York
Frank J. Rauscher, III
Affiliation:
The Wistar Institute Cancer Centre, Philadelphia
Get access

Summary

Introduction

STAT proteins (Signal Transducers and Activators of Transcripton) are latent cytoplasmic transcription factors that transmit signals from cytokines and growth factors directly to the nucleus. They become activated by tyrosine phosphorylation, which can be induced by growth-factor receptor kinases, cytokine-receptor-associated kinases or other non-receptor tyrosine kinases. Phosphorylated STAT proteins form activated dimers in the cytoplasm, translocate into the nucleus, where they bind to DNA and, in conjunction with other transcription factors, regulate gene expression. These unique properties of STAT proteins – transmitting signals from diverse cytokines and growth factors, which are often overly active in cancer, as well as regulating expression of numerous genes involved in cancer – position some of the STAT family proteins, especially STAT3, to be key mediators of oncogenesis and thus attractive targets for cancer therapy. It is important to recognize that the critical roles of STAT3 in cancer derive from the deregulation of normal physiological functions modulated by STAT3, including wound healing and immune responses to infection, as will become evident in this chapter.

There are seven members of the STAT protein family – STAT1 to STAT4, STAT6, and the closely related STAT5a and STAT5b proteins (Figure 25.1). The STAT family members share several key structural features, including the DNA binding, SH2, and transactivation domains (Figure 25.1). Despite similarities in their structures, the STAT family proteins have distinct functions, in some cases having opposite roles in many aspects of physiology and cancer. For example, STAT1, which is activated by interferon (IFN) stimulation, induces growth restraint, apoptosis, and tumor immune surveillance (1,2). In contrast, STAT3 and to some extent STAT5, promote tumor cell proliferation and survival, as well as suppress anti-tumor immune responses (3,4). Of particular interest for molecular targeting of this pathway are the underlying mechanisms by which STAT3 promotes oncogenesis through control of tumor cell proliferation, survival, angiogenesis, metastasis, and immune evasion.

Type
Chapter
Information
Molecular Oncology
Causes of Cancer and Targets for Treatment
, pp. 305 - 312
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bromberg, J, Darnell, JE The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000;19:2468–73.CrossRef
Shankaran, V, Ikeda, H, Bruce, AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107–11.CrossRef
Yu, H, Jove, R. The STATs of cancer: new molecular targets come of age. Nature Reviews Cancer 2004;4:97–105.CrossRef
Yu, H, Kortylewski, M, Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nature Reviews Immunology 2007;7:41–51.CrossRef
Darnell, JE STATs and gene regulation. Science 1997;277:1630–5.CrossRef
Leonard, WJ, O’Shea, JJ. Jaks and STATs: biological implications. Annual Review Immunology 1998;16:293–322.CrossRef
Catlett-Falcone, R, Landowski, TH, Oshiro, MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999;10:105–15.CrossRef
Naugler, W, Sakurai, T, Kim, S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317:121–4.CrossRef
Yu, H, Pardoll, D, Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nature Reviews Cancer 2009;9:798–809.CrossRef
Langowski, JL, Zhang, X, Wu, L, et al. IL-23 promotes tumour incidence and growth. Nature 2006;442:461–5.CrossRef
Wang, T, Niu, G, Kortylewski, M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nature Medicine 2004;10:48–54.CrossRef
Yu, CL, Meyer, DJ, Campbell, GS, et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 1995;269:81–3.CrossRef
Grandis, JR, Drenning, SD, Chakraborty, A, et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro. Journal of Clinical Investigation 1998;102:1385–92.CrossRefGoogle Scholar
Bromberg, JF, Wrzeszczynska, MH, Devgan, G, et al. Stat3 as an oncogene. Cell 1999;98:295–303.CrossRef
Levy, DE, Darnell, JE Stats: transcriptional control and biological impact. Nature Reviews Molecular and Cellular Biology 2002;3:651–62.CrossRef
Lee, H, Herrmann, A, Deng, JH, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009;15:283–93.CrossRef
Hanahan, D, Weinberg, RA. The hallmarks of cancer. Cell 2000;100:57–70.CrossRef
Kortylewski, M, Kujawski, M, Wang, T, et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nature Medicine 2005;11:1314–21.CrossRef
Dunn, GP, Koebel, CM, Schreiber, RD. Interferons, immunity and cancer immunoediting. Nature Reviews Immunology 2006;6:836–48.CrossRef
Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Reviews Cancer 2005;5:263–74.CrossRef
Takeda, K, Clausen, BE, Kaisho, T, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999;10:39–49.CrossRef
Welte, T, Zhang, SS, Wang, T, et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proceedings of the National Academy of Science USA 2003;100:1879–84.CrossRef
Chiarle, R, Simmons, WJ, Cai, H, et al. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nature Medicine 2005;11:623–9.CrossRef
Okada, S, Nakamura, M, Katoh, H, et al. Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury. Nature Medicine 2006;12:829–34.CrossRef
Dauer, DJ, Ferraro, B, Song, L, et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005;24:3397–408.CrossRef
Hedvat, M, Huszar, D, Herrmann, A, et al. The Jak2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009;16:487–97.CrossRef
Darnell, JE. Transcription factors as targets for cancer therapy. Nature Reviews Cancer 2002;2:740–9.CrossRef
Siddiquee, KA, Gunning, PT, Glenn, M, et al. An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chemical Biology 2007;2:787–98.CrossRef
Minegishi, Y, Saito, M, Tsuchiya, S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007;448:1058–62.CrossRef
Kortylewski, M, Swiderski, P, Herrmann, A, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nature Biotechnology 2009;27:925–32.CrossRef

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×